Clinical Trial Update: Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) [Phase 2]

View source ↗

Summary

A Phase 2 trial assesses neoadjuvant chemotherapy combined with a PD-1 inhibitor for head and neck squamous cell carcinoma with the goal of de-escalation of sub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hpv-associated Oropharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Sinonasal Squamous Cell Carcinoma
• Skull Base Tumors

Drugs mentioned

• PD-1 inhibitor

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Head and Neck Cancer, Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING